[The value of PSA follow-up in recurrent prostate carcinoma after radical prostatovesiculectomy].
We report our experience in evaluating PSA-follow-up of patients treated with radical prostatectomy. Also PSA is the most sensitive available screening test for relapse after radical prostatectomy, it is not 100% specific for cancer relapse while this serum marker is not specific for prostate cancer. In our opinion, patients with biochemical relapse (PSA > 0.5 ng/l) should undergo an early restaging including biopsy of the anastomosis. In 57% of our patients with PSA > 1.0 ng/l two months after surgery we found clinical recurrence 27 months later on.
Trinkler
F
F
Urologische Klinik, Universitätsspital Zürich.
Hauri
D
D
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D015653:Cystectomy; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D011183:Postoperative Complications / Q000097:blood / Q000175:diagnosis / Q000601:surgery; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000601:surgery
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen